During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.

Knocking down EPIC1 sensitized triple negative breast tumor-bearing mice to immunotherapy with the PD-1 inhibitor pembrolizumab.

“These results from EV-303 represent a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer, demonstrating the potential of PADCEV in combination with KEYTRUDA when used ...

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed manageable toxicity among patients metastatic nonsquamous non-small cell lung cancer ...